GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » MedAvail Holdings Inc (OTCPK:MDVLQ) » Definitions » Peter Lynch Fair Value

MedAvail Holdings (MedAvail Holdings) Peter Lynch Fair Value : N/A (As of May. 28, 2024)


View and export this data going back to 2020. Start your Free Trial

What is MedAvail Holdings Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.


The historical rank and industry rank for MedAvail Holdings's Peter Lynch Fair Value or its related term are showing as below:



MDVLQ's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 1.34
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


MedAvail Holdings Peter Lynch Fair Value Historical Data

The historical data trend for MedAvail Holdings's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedAvail Holdings Peter Lynch Fair Value Chart

MedAvail Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Peter Lynch Fair Value
- - - -

MedAvail Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of MedAvail Holdings's Peter Lynch Fair Value

For the Pharmaceutical Retailers subindustry, MedAvail Holdings's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedAvail Holdings's Price-to-Peter-Lynch-Fair-Value Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, MedAvail Holdings's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where MedAvail Holdings's Price-to-Peter-Lynch-Fair-Value falls into.



MedAvail Holdings Peter Lynch Fair Value Calculation

MedAvail Holdings's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* N/A *-36
=N/A

MedAvail Holdings's EPS without NRI for the trailing twelve months (TTM) uses the latest annual data, which was $-36.00.

* Note that for companies that do not have enough quarterly data to calculate the 5-Year TTM EBITDA Growth Rate, we use the annual data for the calculation.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


MedAvail Holdings  (OTCPK:MDVLQ) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 0 instead of 15 in this case.

MedAvail Holdings's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=0.0003/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MedAvail Holdings Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of MedAvail Holdings's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


MedAvail Holdings (MedAvail Holdings) Business Description

Traded in Other Exchanges
N/A
Address
4720 East Cotton Gin Loop, Suite 220, Phoenix, AZ, USA, 85040
MedAvail Holdings Inc is a telehealth-enabled pharmacy technology company. It operates in two segments: Retail Pharmacy Services and Pharmacy Technology. It generates the majority of revenue from the Retail Pharmacy Services segment, which is into operating SpotRx, a full-service retail pharmacy utilizing MedAvail's automated pharmacy technology, primarily servicing Medicare patients in the United States. The Pharmacy Technology segment develops and commercializes the MedCenter for direct sale or lease to third-party customers.
Executives
Ramona Seabaugh officer: Chief Financial Officer C/O MEDAVAIL TECHNOLOGIES INC., 6665 MILLCREEK DR, UNIT 1, MISSISSAUGA A6 L5N 5M4
Michael R Kramer director 3910 BRICKWAY BLVD, SANTA ROSA CA 95403
Paul D Johnson director 440 N BARRANCA AVE #3550, COVINA CA 91723
Glen D. Stettin director C/O EXPRESS SCRIPTS HOLDING COMPANY, ONE EXPRESS WAY, ST. LOUIS MO 63121
Mark Edward Doerr director, officer: Chief Executive Officer C/O MEDAVAIL TECHNOLOGIES INC., 6665 MILLCREEK DR, UNIT 1, MISSISSAUGA A6 L5N 5M4
Abg Wtt-medavail Ltd 10 percent owner 15 QUEENS ROAD CENTRAL, UNIT 3002-3004, 30TH FLOOR, GLOUCESTER TWR, THE LANDMARK, HONG KONG F4 0000000000
Redco Ii Master Fund, L.p. director, 10 percent owner ONE LETTERMAN DRIVE, BLDG D, STE D3-300, SAN FRANCISCO CA 94129
Alyeska Fund Gp, Llc 10 percent owner 77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Alyeska Investment Group, Llc 10 percent owner 77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Alyeska Investments, Llc 10 percent owner 77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Anand Parekh 10 percent owner 77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Alyeska Master Fund, L.p. 10 percent owner 77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Alyeska Investment Group, L.p. 10 percent owner 77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Steven Hess officer: Executive Vice President C/O MEDAVAIL TECHNOLOGIES INC., 6665 MILLCREEK DR, UNIT 1, MISSISSAUGA A6 L5N 5M4
Edwin Kilroy director, officer: Chief Executive Officer C/O MEDAVAIL TECHNOLOGIES INC., 6665 MILLCREEK DR, UNIT 1, MISSISSAUGA A6 L5N 5M4

MedAvail Holdings (MedAvail Holdings) Headlines